Dear Sirs,

Covid-19 infection has been associated with a predominant prothrombotic state causing venous and arterial thrombosis \[[@CR1]\]. Although cerebrovascular complications were reported in 0.8% and in 5.7% of the patients with non-severe and severe Covid-19 disease \[[@CR2]\], respectively, they were associated with 2.5-fold increased odds of severe disease in patients with Covid-19 infection \[[@CR3]\]. Previous case reports or case series described patients with Covid-19 infection who developed acute stroke \[[@CR4]--[@CR12]\]. Here, we describe the clinical features, neuroimaging and laboratory findings of a case series of patients with Covid-19 infection consecutively admitted to our hyper-acute stroke unit (HASU), Charing Cross Hospital, Imperial College Health Care NHS Trust (ICHT) with acute stroke via the acute stroke pathway. From the 1 March to 30 April 2020, eight acute stroke patients who tested positive for Covid-19 were consecutively admitted to our HASU. Seven out of eight patients suffered an ischemic stroke, with one patient with a haemorrhagic stroke. The median age of our patients was 74 years old (IQR 11.8), and the median NIHSS on admission was 8.5 (IQR 6.3) (Table [1](#Tab1){ref-type="table"}). Our patients developed the symptoms of stroke after a median interval time of 7 days (IQR 10.5) after the onset of their Covid-19 infection. Of note, three patients out of eight showed the neurological symptoms of stroke at the same time as the symptoms of the Covid-19 infection. In the seven patients with ischemic stroke, the majority were in the anterior circulation (*n* = 6). Large vessel occlusion or floating thrombus in a large vessel was seen in three patients (Fig. [1](#Fig1){ref-type="fig"}). Multiple ischemic infarcts were documented in 5 cases out of 7 of which three patients had bilateral lesions. The size of the infarct was classified as small in four cases \[[@CR13]\]. One patient (no. 7) was treated successfully with intravenous thrombolysis with tissue plasminogen activator (t-PA) at 3 h and 15 min after the onset of his symptoms. After 24 h, his NIHSS dropped from 8 to 3 and he was discharged after three days with no neurological symptoms and being functionally independent (mRs 0). Table [2](#Tab2){ref-type="table"} shows the laboratory and radiologic findings on admission for our patients. Most of our patients had elevated levels of fibrinogen, D-dimer and C-reactive protein. In three out of the four, the patients with severe Covid-19 lymphocytopenia were present while one patient (no. 3) showed an abnormal elevated lymphocyte count in the context of chronic lymphocytic leukemia.Table 1Clinical characteristics of the eight patients with acute strokePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Age (years), sex63, F83, M88, M77, M71, M55, M79, M70, MOnset of Neurologic syndromeConcomitant with fever and dyspnea11 Days after fever and dyspnea12 Days after fever, malaise, dyspneaConcomitant with dyspnea and cough1 Day before dyspnea and tachypnea10 Days after cough and anosmiaAfter 7 Days of cough and feverConcomitant with fever and coughSeverity of COVID infectionSevereSevereSevere, developed ARDSSevereModerateModerateModerateModerateType of stroke; TOAST classification^a^Ischemic stroke with small lesions in the anterior circulation; undetermined etiology for incomplete evaluationIschemic stroke with small lesions in the anterior circulation; cardioembolicIschemic stroke with a small lesion in the posterior circulation; cardioembolicIschemic stroke with a medium lesion in the anterior circulation; cardioembolicIschemic stroke with a medium lesion in the anterior circulation; undetermined etiology for incomplete evaluationsHaemorragic stroke likely hypertensiveIschemic stroke with small lesions in the anterior circulation; undetermined etiology for incomplete evaluationsIschemic stroke with a medium lesion in the anterior circulation; cardioembolicComorbid conditionsPeripheral vascular disease, ischemic coronary artery disease, hypertensionNew onset of Atrial fibrillationProstate cancer, known atrial fibrillation, previous intracranial haemorrhage, COPD, hypertensionNeuroendocrine tumor in the colon, diabetes type 2, smoking, hypertensionHypertension, smokingDiabetes type 2, Hypercholesterolemia, previous TIAs, hypertensionDiabetes type 2, atrial fibrillation, coronary artery diseaseNIHSS on admission and signs/symptoms of stroke9; neglect, dysaphasia, left arm paresis19; dysphasia, right hemiplegia, sensory deficit, gaze preference, facial droop3; facial droop, right hemiparesis13; dysarthria, dysphasia, right hemiparesis12; right hemianopia, right hemiparesis, dysphasia, dysarthria2; right arm paresis and ataxia8 and 3 after 24 h; dysphasia, right arm paresis, sensory deficit7; dysphasia, inattention and dysarthriaBrain scan resultsMultiple and Bilateral infarctsMultiple infarcts; floating thrombus in the left ICASingle infarctMultiple and bilateral infarctsMultiple infarcts with hemorrhagic transformation type PH1; floating thrombus in the left ICASmall intracranial haemorrhage in the left external capsuleNo acute infarct on first CT; 24 h MRI showed multiple and bilateral infarcts with hemorrhagic transformation type HI-1Single infarct with M1/M2 junction large vessel occlusionTreatment and outcomesReceived 14 days of Aspirin 300 mg followed by Clopidogrel 75 mg; discharged at home after 7 days with mRs of 3Received LMWH; still inpatient with mRs of 5Received 14 days of Aspirin 300 mg followed by Apixaban; still inpatient with mRs of 1Received Apixaban; discharged at home after 26 days with mRs of 3Received LMWH; still inpatient with mRs of 1Received antihypertesive medications; discharged at home after 6 days with mRs of 0Received iv. Alteplase and 14 days of Aspirin 300 mg followed by Clopidogrel 75 mg; discharged at home after 3 days with mRs of 0; re-admitted after 30 days with a new TIAReceived 14 days of Aspirin 300 mg followed by Clopidogrel 75 mg; still inpatient with mRs of 3*F* female, *M* male, *NIHSS* National Institutes of Health Stroke Scale, *mRs* modified Rankin Scale, *ICA* internal carotid artery, *LMWH* low molecular weight heparin, *TIA* transient ischemic attack^a^TOAST Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Classification applied for ischemic stroke onlyFig. 1Case 5. **A** CT angiography demonstrates lobulated soft tissued plaque at the left common carotid artery bifurcation which involves the origin of the left internal carotid artery, causing approximately 50% narrowing of the left ICA origin and in keeping with a floating thrombus. The chest XR shows diffuse bilateral air space opacifications. Case 2. **B** CT angiography illustrates a mixture of soft tissue and calcified mural plaque with an intraluminal tail of thrombus extending into the Internal Carotid Artery. The Chest CT shows bilateral predominantly peripheral interstitial and airspace opacifications as well as bronchocentric opacities predominantly in the lower lobes. Case 8. **C** CT angiography demonstrates acute left middle cerebral artery M1/M2 junction occlusion, and the MRI brain shows acute infarct of the left anterolateral temporal lobe. The chest XR shows bilateral peripheral predominant multiple opacitiesTable 2Radiological and laboratory findings of the eight patients with acute strokePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Chest XR/CT resultsBilateral consolidations with small pleural effusionsMultifocal bilateral GGOMultifocal bilateral GGO and bilateral pleural effusionsUnilateral consolidationMultifocal bilateral GGONo abnormalitiesMultifocal, Unilateral GGOMultifocal, Bilateral GGOWhite blood cell count (4.2--7.0 × 10^9^/L)5.65.127.47.29.56.54.811.4Lymphocyte count (1.1--3.6 × 10^9^/L)0.60.718.90.71.81.21.11.8Platelet count (130--370 × 10^9^/L)132376225214590232148634CRP (\< 5.0 mg/L)8.4213.4279.296.244.39818.680.7Fibrinogen (1.90--4.30 g/L)4.217.599.824.965.264.895.177.8APTT (seconds) (25--35)\> 18074.832.338.830.324.730.228.6Prothrombin time (seconds) (12.8--17.4)13.018.118.719.214.811.813.914D-Dimer level (\< 500 ng/mL)97091256\> 200038461557----5952*GGO* ground-glass-opacity

Our case series provided descriptive data on patients with Covid-19 disease that developed acute stroke and were admitted to our HASU via the acute stroke pathways. A recent WSO survey across multiple countries including UK, Italy, Belgium, Greece, Iran, Chile and Colombia has documented that the Covid-19 pandemic has affected the stroke care with a significant fall in the number of stroke admissions, up to 80%, during the COVID-19 outbreak \[[@CR14]\]. Moreover, preliminary data suggested that a smaller proportion of patients with milder stroke symptoms presented to hospital during the COVID-19 pandemic \[[@CR15]\] due to fears of infection. The median NIHSS on admission of our patient sample was 8.5 suggesting that these more severe symptoms cannot be ignored by patients or family members.

Previous studies described the clinical characteristics and course of acute stroke in patients with Covid-19 disease in different healthcare systems compared to ours \[[@CR4], [@CR16]\]. Compared to the case series of Oxley et al. \[[@CR4]\], most of our patients with ischemic stroke had multiple and small ischemic lesions on the brain scans. Interestingly, as also documented in the case series of Avula et al. \[[@CR17]\], we showed three patients with acute stroke as a presenting symptom.

The presence of Covid-19 infection has been associated with a predominant prothrombotic state \[[@CR1]\] affecting the fibrinolysis and regulated by various pro-inflammatory cytokines \[[@CR18]\].

In our case series, the severe Covid-19 patients were commonly associated with markedly elevated D-dimer, high fibrinogen and elevated APTT levels. This is in line with previous studies suggesting a more pronounced microvascular thrombosis associated with Covid-19 than those induced by non-SARS-CoV2 \[[@CR19]\].

As the inflammatory processes have fundamental roles in stroke in either the aetiology and pathophysiology of cerebral ischemia \[[@CR20]\], the presence of Covid-19 infection could be a factor in the genesis or worsening of stroke in addition to the potential risk of cardioembolic stroke due to ACE-2 expression in the heart and subsequent cardiac dysfunction \[[@CR21]\].

Taken together, our case series highlights the importance of investigating the role of the Covid-19 in the aetiology and pathophysiology of the cerebrovascular disease as a complication of the disease. Viral infections can trigger stroke with different mechanisms that depend on the associated pathogen and host characteristics. Varicella zoster virus (VZV) is responsible for a distinctive vasculopathy involving both large and small arteries \[[@CR22]\], while human immunodeficiency virus (HIV) can cause brain large vessel vasculopathy \[[@CR23]\]. Data acquisition of larger case series is urgently needed to investigate the potential causative association between Covid-19 and stroke. We believe that, if proven, this would emphasize the importance of early detection of stroke symptoms in Covid-19 patients to allow better identification of those patients who could benefit from reperfusion therapy. In conclusion, we believe that our case description provides further evidence of the heterogeneous neurological complications associated with SARS-CoV-2. Future researches and data acquisition are needed to characterize the casual association and the clinical pattern of new cases of acute stroke observed in the context of Covid-19 pandemic.
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